Literature DB >> 15784335

Multivariate modeling of cytochrome P450 3A4 inhibition.

Jan M Kriegl1, Lennart Eriksson, Thomas Arnhold, Bernd Beck, Erik Johansson, Thomas Fox.   

Abstract

In the early phases of current pharmaceutical research projects, huge numbers of compounds are tested on their biological activity with respect to a certain target by experimental or virtual screening campaigns. To reduce the attrition rate in later stages of a project, other relevant properties such as physicochemical and ADMET (absorption, distribution, metabolism, excretion, toxicity) properties should be assessed as early as possible in lead discovery and optimization. The present study describes the development of in silico models to predict the inhibition of human cytochrome P450 3A4 (CYP3A4) from calculated molecular descriptors. The models were trained and validated using a set of 967 structural diverse drug-like research compounds with an experimentally determined CYP3A4 inhibition potency (IC50 value) which was carefully split into a training and a test set. For classification models, the data sets were further subdivided into strong, medium, and weak inhibitors. Different descriptor sets were used to cover various aspects of molecular properties, including properties derived from the 2D structure, the interaction of the molecule with its environment, and properties derived from quantum-mechanical calculations. The descriptors were related to the CYP3A4 inhibition potency by multivariate data analysis methods such as partial least-squares projection to latent structures (PLS), PLS discriminant analysis (PLS-DA), and soft independent class modeling (SIMCA). The squared correlation between experimental and predicted IC50 values of the previously unseen test set compounds was Qext2=0.6 for the best PLS models, corresponding to a root mean squared error (RMSE) of RMSE=0.45 (logarithm of IC50). The best PLS-DA models were able to correctly classify more than 60% of the test set compounds, whereas almost no strong inhibitors were wrongly classified as weak inhibitors and vice versa. Furthermore, relevant molecular properties were identified which are closely related to the CYP3A4 inhibition potency of a compound. The results presented here are very encouraging since our models could, for instance, serve to flag problematic compounds or to guide further synthesis efforts.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15784335     DOI: 10.1016/j.ejps.2004.12.009

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  5 in total

1.  Different effects of dihydropyridine calcium channel antagonists on CYP3A4 enzyme of human liver microsomes.

Authors:  Zongling Xia; Mingli Wang; Sulan Zou; Rong Chen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-12-13       Impact factor: 2.441

2.  Trainable structure-activity relationship model for virtual screening of CYP3A4 inhibition.

Authors:  Remigijus Didziapetris; Justas Dapkunas; Andrius Sazonovas; Pranas Japertas
Journal:  J Comput Aided Mol Des       Date:  2010-09-01       Impact factor: 3.686

3.  Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors.

Authors:  Vasanthanathan Poongavanam; Norbert Haider; Gerhard F Ecker
Journal:  Bioorg Med Chem       Date:  2012-03-29       Impact factor: 3.641

4.  Ligand and structure-based classification models for prediction of P-glycoprotein inhibitors.

Authors:  Freya Klepsch; Poongavanam Vasanthanathan; Gerhard F Ecker
Journal:  J Chem Inf Model       Date:  2014-01-09       Impact factor: 4.956

5.  Modeling chemical interaction profiles: II. Molecular docking, spectral data-activity relationship, and structure-activity relationship models for potent and weak inhibitors of cytochrome P450 CYP3A4 isozyme.

Authors:  Yunfeng Tie; Brooks McPhail; Huixiao Hong; Bruce A Pearce; Laura K Schnackenberg; Weigong Ge; Dan A Buzatu; Jon G Wilkes; James C Fuscoe; Weida Tong; Bruce A Fowler; Richard D Beger; Eugene Demchuk
Journal:  Molecules       Date:  2012-03-15       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.